Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc.verified

ONCT

Price:

$0.5266

Market Cap:

$1.56M

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen r...[Read more]

Industry

Biotechnology

IPO Date

2004-02-03

Stock Exchange

NASDAQ

Ticker

ONCT

The Enterprise Value as of December 2024 (TTM) for Oncternal Therapeutics, Inc. (ONCT) is -11329454.00

According to Oncternal Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -11329454.00. This represents a change of -186.69% compared to the average of 13.07M of the last 4 quarters.

Oncternal Therapeutics, Inc. (ONCT) Historical Enterprise Value (quarterly & annually)

How has ONCT Enterprise Value performed in the past?

The mean historical Enterprise Value of Oncternal Therapeutics, Inc. over the last ten years is 952.23M. The current -11329454.00 Enterprise Value has changed -218.98% with respect to the historical average. Over the past ten years (40 quarters), ONCT's Enterprise Value was at its highest in in the March 2021 quarter at 8.06B. The Enterprise Value was at its lowest in in the September 2024 quarter at -8980800.00.

Quarterly (TTM)
Annual

Average

952.23M

Median

203.83M

Minimum

-17202500.00

Maximum

4.42B

Oncternal Therapeutics, Inc. (ONCT) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Oncternal Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 189.02%

Maximum Annual Enterprise Value = 4.42B

Minimum Annual Increase = -223.64%

Minimum Annual Enterprise Value = -17202500.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202325.14M61.77%
202215.54M-26.94%
202121.27M-223.64%
2020-17202500.00-182.16%
201920.94M-94.53%
2018382.53M-91.34%
20174.42B189.02%
20161.53B-21.65%
20151.95B65.83%
20141.18B-43.06%

Oncternal Therapeutics, Inc. (ONCT) Average Enterprise Value

How has ONCT Enterprise Value performed in the past?

The current Enterprise Value of Oncternal Therapeutics, Inc. (ONCT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

20.65M

5-year avg

13.14M

10-year avg

952.23M

Oncternal Therapeutics, Inc. (ONCT) Enterprise Value vs. Peers

How is ONCT’s Enterprise Value compared to its peers?

Oncternal Therapeutics, Inc.’s Enterprise Value is less than Neoleukin Therapeutics, Inc. (0), less than CytomX Therapeutics, Inc. (-6333315.00), less than Assembly Biosciences, Inc. (53.76M), less than Instil Bio, Inc. (66.94M), less than Nuvation Bio Inc. (221.53M), less than Protara Therapeutics, Inc. (910.08M), less than Vaccinex, Inc. (130.41M), less than Monopar Therapeutics Inc. (311.44K), less than Miromatrix Medical Inc. (110.36M), less than Surrozen, Inc. (90.06M), less than Passage Bio, Inc. (10.29M), less than Absci Corporation (33.76M), less than Adverum Biotechnologies, Inc. (319.51M), less than Kezar Life Sciences, Inc. (79.02M), less than Armata Pharmaceuticals, Inc. (29.92M), less than Pasithea Therapeutics Corp. (197.00M), less than Aditxt, Inc. (-6093787.00), less than null (12.41M),

Build a custom stock screener for Oncternal Therapeutics, Inc. (ONCT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncternal Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Oncternal Therapeutics, Inc. (ONCT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Oncternal Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Oncternal Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Oncternal Therapeutics, Inc. (ONCT)?

What is the 3-year average Enterprise Value for Oncternal Therapeutics, Inc. (ONCT)?

What is the 5-year average Enterprise Value for Oncternal Therapeutics, Inc. (ONCT)?

How does the current Enterprise Value for Oncternal Therapeutics, Inc. (ONCT) compare to its historical average?